Pantheon, LGT back early-stage biotech restructuring
The deal involving Medicxi was based around six assets and completed at a premium to NAV, co-founder Francesco De Rubertis told Secondaries Investor.
The deal involving Medicxi was based around six assets and completed at a premium to NAV, co-founder Francesco De Rubertis told Secondaries Investor.
Copyright PEI Media
Not for publication, email or dissemination